Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.44
AMAG's Cash to Debt is ranked lower than
86% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AMAG: 0.44 )
Ranked among companies with meaningful Cash to Debt only.
AMAG' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 10000.00 Max: No Debt
Current: 0.44
Equity to Asset 0.36
AMAG's Equity to Asset is ranked lower than
79% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMAG: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
AMAG' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.74 Max: 0.98
Current: 0.36
0.33
0.98
Interest Coverage 2.04
AMAG's Interest Coverage is ranked lower than
95% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: 2.04 )
Ranked among companies with meaningful Interest Coverage only.
AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: 2.04
F-Score: 4
Z-Score: 0.54
M-Score: 6.48
WACC vs ROIC
3.59%
7.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 23.48
AMAG's Operating margin (%) is ranked higher than
87% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. AMAG: 23.48 )
Ranked among companies with meaningful Operating margin (%) only.
AMAG' s Operating margin (%) Range Over the Past 10 Years
Min: -4107.64  Med: -337.51 Max: -3.08
Current: 23.48
-4107.64
-3.08
Net-margin (%) 46.47
AMAG's Net-margin (%) is ranked higher than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. AMAG: 46.47 )
Ranked among companies with meaningful Net-margin (%) only.
AMAG' s Net-margin (%) Range Over the Past 10 Years
Min: -3696.96  Med: -322.94 Max: 109.19
Current: 46.47
-3696.96
109.19
ROE (%) 28.47
AMAG's ROE (%) is ranked higher than
96% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. AMAG: 28.47 )
Ranked among companies with meaningful ROE (%) only.
AMAG' s ROE (%) Range Over the Past 10 Years
Min: -86.79  Med: -32.45 Max: 42.96
Current: 28.47
-86.79
42.96
ROA (%) 11.01
AMAG's ROA (%) is ranked higher than
90% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. AMAG: 11.01 )
Ranked among companies with meaningful ROA (%) only.
AMAG' s ROA (%) Range Over the Past 10 Years
Min: -67.05  Med: -26.38 Max: 16.42
Current: 11.01
-67.05
16.42
ROC (Joel Greenblatt) (%) 256.66
AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. AMAG: 256.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMAG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1009.91  Med: -621.53 Max: -157.21
Current: 256.66
-1009.91
-157.21
Revenue Growth (3Y)(%) 19.50
AMAG's Revenue Growth (3Y)(%) is ranked higher than
78% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AMAG: 19.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMAG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.2  Med: 15.25 Max: 265.9
Current: 19.5
-31.2
265.9
» AMAG's 10-Y Financials

Financials (Next Earnings Date: 2016-02-17)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AMAG Guru Trades in Q1 2015

Paul Tudor Jones 38,762 sh (+359.76%)
Ken Heebner 522,000 sh (unchged)
» More
Q2 2015

AMAG Guru Trades in Q2 2015

Joel Greenblatt 510,597 sh (New)
Paul Tudor Jones 139,125 sh (+258.92%)
Ken Heebner 522,000 sh (unchged)
» More
Q3 2015

AMAG Guru Trades in Q3 2015

Scott Black 131,240 sh (New)
Jim Simons 17,660 sh (New)
David Dreman 280 sh (New)
Chuck Royce 19,900 sh (New)
Joel Greenblatt 996,545 sh (+95.17%)
Ken Heebner 472,000 sh (-9.58%)
Paul Tudor Jones 15,800 sh (-88.64%)
» More
Q4 2015

AMAG Guru Trades in Q4 2015

Jim Simons 160,260 sh (+807.47%)
David Dreman Sold Out
Ken Heebner Sold Out
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 4.55
AMAG's P/E(ttm) is ranked higher than
94% of the 390 Companies
in the Global Biotechnology industry.

( Industry Median: 26.50 vs. AMAG: 4.55 )
Ranked among companies with meaningful P/E(ttm) only.
AMAG' s P/E(ttm) Range Over the Past 10 Years
Min: 4.55  Med: 11.58 Max: 15.65
Current: 4.55
4.55
15.65
Forward P/E 3.94
AMAG's Forward P/E is ranked higher than
92% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 16.50 vs. AMAG: 3.94 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 4.64
AMAG's PE(NRI) is ranked higher than
93% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. AMAG: 4.64 )
Ranked among companies with meaningful PE(NRI) only.
AMAG' s PE(NRI) Range Over the Past 10 Years
Min: 4.64  Med: 11.67 Max: 15.81
Current: 4.64
4.64
15.81
P/B 0.84
AMAG's P/B is ranked higher than
90% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. AMAG: 0.84 )
Ranked among companies with meaningful P/B only.
AMAG' s P/B Range Over the Past 10 Years
Min: 0.84  Med: 2.71 Max: 18.97
Current: 0.84
0.84
18.97
P/S 2.07
AMAG's P/S is ranked higher than
87% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.77 vs. AMAG: 2.07 )
Ranked among companies with meaningful P/S only.
AMAG' s P/S Range Over the Past 10 Years
Min: 2.07  Med: 11.43 Max: 496.73
Current: 2.07
2.07
496.73
PFCF 10.90
AMAG's PFCF is ranked higher than
79% of the 269 Companies
in the Global Biotechnology industry.

( Industry Median: 27.55 vs. AMAG: 10.90 )
Ranked among companies with meaningful PFCF only.
AMAG' s PFCF Range Over the Past 10 Years
Min: 10.89  Med: 29.93 Max: 328.2
Current: 10.9
10.89
328.2
POCF 10.90
AMAG's POCF is ranked higher than
78% of the 395 Companies
in the Global Biotechnology industry.

( Industry Median: 27.92 vs. AMAG: 10.90 )
Ranked among companies with meaningful POCF only.
AMAG' s POCF Range Over the Past 10 Years
Min: 10.89  Med: 45.63 Max: 1268.5
Current: 10.9
10.89
1268.5
EV-to-EBIT 19.50
AMAG's EV-to-EBIT is ranked lower than
51% of the 452 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. AMAG: 19.50 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -787.3  Med: -6.30 Max: 87.5
Current: 19.5
-787.3
87.5
EV-to-EBITDA 10.49
AMAG's EV-to-EBITDA is ranked higher than
66% of the 479 Companies
in the Global Biotechnology industry.

( Industry Median: 15.17 vs. AMAG: 10.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -273.7  Med: -6.20 Max: 479.9
Current: 10.49
-273.7
479.9
Current Ratio 2.46
AMAG's Current Ratio is ranked lower than
69% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. AMAG: 2.46 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.65  Med: 8.10 Max: 54.4
Current: 2.46
1.65
54.4
Quick Ratio 2.32
AMAG's Quick Ratio is ranked lower than
66% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AMAG: 2.32 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 7.65 Max: 54.33
Current: 2.32
1.4
54.33
Days Inventory 163.65
AMAG's Days Inventory is ranked lower than
62% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. AMAG: 163.65 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 300  Med: 506.54 Max: 1713.48
Current: 163.65
300
1713.48
Days Sales Outstanding 74.14
AMAG's Days Sales Outstanding is ranked lower than
56% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. AMAG: 74.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.61  Med: 31.89 Max: 581.14
Current: 74.14
11.61
581.14
Days Payable 17.86
AMAG's Days Payable is ranked lower than
80% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. AMAG: 17.86 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 80.23  Med: 901.87 Max: 6362.77
Current: 17.86
80.23
6362.77

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.14
AMAG's Price/Projected FCF is ranked higher than
86% of the 283 Companies
in the Global Biotechnology industry.

( Industry Median: 2.87 vs. AMAG: 1.14 )
Ranked among companies with meaningful Price/Projected FCF only.
AMAG' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.12  Med: 9.76 Max: 96.83
Current: 1.14
2.12
96.83
Price/Median PS Value 0.19
AMAG's Price/Median PS Value is ranked higher than
95% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. AMAG: 0.19 )
Ranked among companies with meaningful Price/Median PS Value only.
AMAG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 1.20 Max: 138.58
Current: 0.19
0.29
138.58
Earnings Yield (Greenblatt) (%) 5.05
AMAG's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. AMAG: 5.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMAG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 3.00 Max: 5.06
Current: 5.05
1.1
5.06

More Statistics

Revenue(Mil) $363
EPS $ 6.37
Beta1.22
Short Percentage of Float29.01%
52-Week Range $20.48 - 77.73
Shares Outstanding(Mil)34.70

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 400 532 686 628
EPS($) 4.07 4.72 5.43 4.60
EPS without NRI($) 4.07 4.72 5.43 4.60

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company that markets Feraheme Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors who, in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers and nephrology clinics. In addition, it also outsource a number of its product supply chain services to ICS, its third-party logistics provider, including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. The Company is subject to extensive additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S.
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
Who Will Come Out On Top As Flu Season Draws Down Feb 10 2016
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Feb 08 2016
AMAG Pharmaceuticals to Host Conference Call on February 17, 2016 at 8:00 a.m. ET to Discuss... Feb 04 2016
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences Feb 02 2016
Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now Jan 28 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud... Jan 27 2016
Coverage initiated on AMAG Pharma by Barclays Jan 21 2016
Why These 4 Stocks Have Started the Week Off on the Right Foot Jan 11 2016
AMAG Pharmaceuticals Announces Preliminary 2015 Financial Results and Provides 2016 Financial... Jan 11 2016
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 11 2016
AMAG Pharmaceuticals Announces Preliminary 2015 Financial Results and Provides 2016 Financial... Jan 11 2016
AMAG Pharmaceuticals Announces $60 Million Share Repurchase Program Jan 06 2016
AMAG Pharmaceuticals Announces $60 Million Share Repurchase Program Jan 06 2016
AMAG Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
AMAG Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer Jan 04 2016
AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer Jan 04 2016
AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : December 30,... Dec 30 2015
Top Analyst Upgrades and Downgrades from Monday: AMAG, Nike, Cempra, Discovery, HCI Group and More Dec 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK